The VITEK 2 Gram Negative Susceptibility Card is intended for use with the VITEK 2 Systems in cli...

FDA Device Recall #Z-2168-2018 — Class II — March 23, 2018

Recall Summary

Recall Number Z-2168-2018
Classification Class II — Moderate risk
Date Initiated March 23, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm BioMerieux SA
Location Marcy L'Etoile, N/A
Product Type Devices
Quantity 135 (78 boxes of various product) in total

Product Description

The VITEK 2 Gram Negative Susceptibility Card is intended for use with the VITEK 2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of clinically significant aerobic gram negative bacilli to antimicrobial agents. Fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.

Reason for Recall

A shipment to Guadeloupe suffered a temperature excursions up to 47.8¿C, exceeding the acceptable limits. After detection of the issue, Global Supply Chain QA asked the bioM¿rieux distributor in Guadeloupe to put products in quarantine in July 2017; After several reminders, the distributor informed in November 2017 that products were delivered to customers.

Distribution Pattern

International distribution.

Lot / Code Information

VITEK¿ 2 AST-N233 (ref: 413117): Lot Number 6330343103

Other Recalls from BioMerieux SA

Recall # Classification Product Date
Z-0084-2022 Class II MYLA Versions: 4.7, 4.7.1, 4.8, 4.8.1 and 4.8.2... Sep 2, 2021
Z-2225-2021 Class II MYLA software. Used to manage microbiology tes... Jun 22, 2021
Z-0218-2019 Class II NucliSENS¿ Magnetic Extraction Reagents Sep 17, 2018
Z-2331-2018 Class II VIDAS FSH, Ref 30407-01, IVD, Rx. The firm nam... Apr 9, 2018
Z-2169-2018 Class II VIDAS TOXO IgG Avidity is an automated qualitat... Mar 23, 2018

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.